Progenics' Azedra gets Priority Review for rare NETs

On Friday, Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) said FDA accepted and granted Priority Review to an NDA for Azedra iobenguane I 131 (Ultratrace I-131-MIBG, Ultratrace iobenguane I 131) to treat malignant recurrent and/or unresectable pheochromocytoma and paraganglioma. Its PDUFA date is April 30.

Progenics said there is no FDA-approved treatment for the rare types of neuroendocrine tumors...